- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/22 - Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
Patent holdings for IPC class A61P 5/22
Total number of patents in this class: 15
10-year publication summary
|
0
|
0
|
0
|
1
|
2
|
0
|
1
|
0
|
0
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Teva Pharmaceuticals International GmbH | 322 |
2 |
| LEO Pharma A/S | 431 |
2 |
| The General Hospital Corporation | 4751 |
1 |
| Kaneka Corporation | 4549 |
1 |
| Amunix Operating Inc. | 26 |
1 |
| Astellas Pharma Inc. | 1083 |
1 |
| Children's Medical Center Corporation | 1876 |
1 |
| Neural Diabetes LLC | 1 |
1 |
| Ouro Fino Saúde Animal LTDA. | 13 |
1 |
| Unigene Laboratories, Inc. | 8 |
1 |
| Universidade de Sao Paulo - USP | 118 |
1 |
| Broad Bean Science Co., Ltd. | 4 |
1 |
| Hangzhou Shixi Pharmaceutical Technology Co., Ltd | 1 |
1 |
| Other owners | 0 |